A pilot randomized phase II study of adjuvant administration of trastuzumab (Herceptin) versus observation after the completion of adjuvant chemotherapy and radiotherapy in patients with stage I-III breast cancer who have detectable disseminated and/or circulating tumor cells (DTCs and/or CTCs) in the bone marrow or/and the peripheral blood before or/and after the completion of adjuvant treatment
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- 29 Feb 2012 Results published in Annals of Oncology.
- 05 Jun 2010 Results presented at ASCO 2010.
- 23 Jan 2008 Status changed from recruiting to completed.